Oxacillinase (OXA)-producing Acinetobacter baumannii in Brazil: Clinical and environmental impact and therapeutic options

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 49, Issue 6, 2013, Pages 391-405

  Medeiros, Micheli ^a   Lincopan, Nilton ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carbapenems; HuHAIs; MLST; Multidrug resistant; OXA 143; OXA 23; Oxacilinases

Indexed keywords

EID: 84892973116     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: 10.1590/S1676-24442013000600003     Document Type: Article

References (162)

1. ADAMS-HADUCH, J. M. et al. Molecular epidemiology of carbapenem- nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol, v. 49, n. 11, p. 3849-54, 2011.
2. ALMEIDA DA SILVA P. E. et al. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother, v. 66, n. 7, p. 1417-30, 2011.
3. ANSALDI, F. et al. Sequential outbreaks of multidrugresistant Acinetobacter baumannii in intensive care units of a tertiary referral hospital in Italy: combined molecular approach for epidemiological investigation. J Hosp Infect, v. 79, n. 2, p. 134-40, 2011.
4. ANTONIO, C. S. et al. Outbreak of multidrug-resistant Acinetobacter baumannii: Characterization of bla-OXA-23-like genes.1° Simpósio Internacional de Microbiologia Clínica (SIMC), Gramado, Rio Grande do Sul, Brasil, 2008.
5. ANTONIO, C. S. et al. Disseminação e emergência de genes blaOXA-23, blaOXA-58, blaOXA-72 e sequências de inserçã o (IS) em isolados de Acinetobacter baumannii resistentes aos carbapenêmicos. In: 25° Congresso Brasileiro de Microbiologia (CBM), Porto de Galinhas, Pernambuco, Brasil, 2009, n. 1508-1.
6. ANTONIO, C. S. et al. High prevalence of carbapenemresistant Acinetobacter baumannii carrying the bla OXA-143 gene in Brazilian hospitals. Antimicrob Agents Chemother, v. 55, n. 3, p. 1322-3, 2011.
7. APPELBAUM, P. C. 2012 and beyond: potential for the start of a second pre-antibiotic era? J Antimicrob Chemother, v. 67, n. 9, p. 2062-8, 2012.
8. BARNAUD, G. et al. Two sequential outbreaks caused by multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 or OXA-72 oxacillinase in an intensive care unit in France. J Hosp Infect, v. 76, n. 4, p. 358-60, 2010.
9. BARTUAL, S.G. et al. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol, v. 43, n. 9, p. 4382-90, 2005.
10. Erratum in: J Clin Microbiol, v. 45, n. 6, p. 2101, 2007.
11. BERGOGNE-BÉRÉZIN, E.; TOWNER, K. J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev, v. 9, n. 2, p.148-65, 1996.
12. BERGOGNE-BÉRÉZIN, E. Treatment of Acinetobacter infections. Expert Opin Investig Drugs, v. 6, n. 2, p. 119-27, 1997.
13. BERTINI, A. et al. First report of the carbapenemhydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrob Agents Chemother, v. 50, n. 6, p. 2268-9, 2006.
14. BISHBURG, E.; BISHBURG, K. Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents, v. 34, n. 5, p. 395-401, 2009.
15. BOO, T. W. et al. First report of OXA-23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic. J Antimicrob Chemother, v. 58, n. 5, p. 1101-2, 2006.
16. BOYD, N.; NAILOR, M. D. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, v. 31, n. 11, p.1073-84, 2011.
17. CALHOUN, J. H. et al. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res, v. 466, n. 6, p.1356-62, 2008.
18. CANDEL, F. J. et al. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter, v. 23, n. 2, p.103-8, 2010.
19. CARVALHO, K. R. et al. Dissemination of multidrugresistant Acinetobacter baumannii genotypes carrying bla (OXA-23) collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents, v. 34, n. 1, p. 25-8, 2009.
20. CARVALHO, K. R. et al. Disseminação de genótipos multirresistentes de Acinetobacter baumannii produtores de carbapenemase OXA-23 em diferentes estados do Brasil. In: 26° Congresso Brasileiro de Microbiologia (CBM), Foz do Iguaçu, Paraná, Brasil, 2011, n. 962-1
21. CARRETTO, E. et al. Widespread carbapenem resistant Acinetobacter baumannii clones in Italian hospitals revealed by a multicenter study. Infect Genet Evol, v. 11, n. 6, p. 1319-26, 2011.
22. CAYÔ, R. et al. Temporal dynamic of carbapenemaseproducing Acinetobacter baumannii (Acb) in a Brazilian teaching hospital through an 18-year period: earlier dissemination of bla OXA-143 in Brazil. 51th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Chicago, IL, USA, 2011. n. C2-645.
23. CLEMENTE, W. T. et al. Fatal outbreak of OXA-143-producing Acinetobacter baumannii in Belo Horizonte, Brazil. 51th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Chicago, IL, USA, 2011. n. C2-644.
24. COELHO, J. et al. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother, v. 50, n. 2, p. 756-8, 2006.
25. DALLA-COSTA, L. M. et al. Outbreak of carbapenemresistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol, v. 41, n. 7, p. 3403-6, 2003.
26. DIJKSHOORN, L. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, v. 5, n. 12, p. 939-51, Review, 2007.
27. ENTENZA, J. M.; MOREILLON, P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents, v. 34, n. 1, p. 8 e1-9, 2009.
28. FERREIRA, A. E. et al. Presence of OXA-23-producing isolates of Acinetobacter baumannii in wastewater from hospitals in southern Brazil. Microb Drug Resist, v. 17, n. 2, p. 221-7, 2011.
29. FIGUEIREDO, D. Q. et al. First report of the bla (OXA-58) gene in a clinical isolate of Acinetobacter baumannii in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz, v.106, n. 3, p. 368-70, 2011.
30. FOURNIER, P. E.; RICHET, H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis, v. 42, n. 5, p. 692-9, 2006.
31. FRANOLI-KUKINA, I. et al. Clonal spread of carbapenemresistant OXA-72-positive Acinetobacter baumannii in a Croatian university hospital. Int J Infect Dis, v. 15, n. 10, p. e706-9, 2011.
32. FU, Y. et al. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J Antimicrob Chemother, v. 65, n. 4, p. 644-50, 2010.
33. GALES, A. C. et al. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol, v. 39, n. 1, p. 183-90, 2001.
34. GALES, A. C. et al. Emergence of an IMP-like metalloenzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis, v. 45, n. 1, p. 77-9, 2003.
35. GALES, A. C. et al. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect, v. 12, n. 4, p. 315-21, 2006.
36. GALES, A. C.et al. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother, v. 66, n. 9, p. 2070-4, 2011.
37. GALES, A. C. et al. Antimicrobial resistance among Gramnegative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis, v. 73, n. 4, p. 354-60, 2012.
38. GARLANTÉZEC, R. et al. Investigation and management of an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak in an intensive care unit. Med Mal Infect, v. 41, n. 8, p. 430-6, 2011.
39. GARRIDO-MESA, N. et al. Minocycline: far beyond an antibiotic. Br J Pharmacol, v. 169, n. 2, p. 337-52, 2013.
40. GIAMARELLOU, H. et al. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents, v. 32, n. 2, p. 106-19, 2008.
41. GIONCO, B. et al. Emergência de uma nova variante de OXA-143 em um isolado clínico de Acinetobacter baumannii resistente aos carbapenêmicos no Hospital Universitário de Londrina. 26° Congresso Brasileiro de Microbiologia (CBM), Foz do Iguaçu, 2011, n.1790-2.
42. GIONCO, B. et al. Detection of OXA-231, a new variant of blaOXA-143, in Acinetobacter baumannii from Brazil: a case report. J Antimicrob Chemother, v. 67, n. 10, p. 2531-2, 2012.
43. GORDON, N. C.; WAREHAM, D. W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents, v. 35, n. 3, p. 219-26, 2010.
44. GORDON, N. C.et al. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother, v. 54, n. 12, p. 5316-22, 2010b.
45. GREENWOOD, D. Antimicrobial Chemotherapy. 4. ed. Oxford: Oxford University Press, 2000. p. 12-28.
46. GROSSO, F. et al. OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro? J Antimicrob Chemother, v. 66, n. 1, p. 62-5, 2011.
47. GUELFI, K. C. et al. In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother, v. 20, n. 2, p. 180-5, 2008.
48. GUERRERO, D. M. et al. Acinetobacter baumanniiassociated skin and soft tissue infections: recognizing a broadening spectrum of disease. Surg Infect (Larchmt), v. 11, n. 1, p. 49-57, 2010.
49. GUR, D. et al. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol, v. 57, n. 12, p. 1529-32, 2008.
50. HÉRITIER, C. et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenemhydrolysing oxacillinase OXA-58. J Antimicrob Chemother, v. 55, n. 1, p. 115-8, 2005a.
51. HÉRITIER, C. et al. Contribution of acquired carbapenemhydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother, v. 49, n. 8, p. 3198-202, 2005b.
52. HIGGINS, P. G. et al. OXA-143, a novel carbapenemhydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother, v. 53, n. 12, p. 5035-8, 2009.
53. HIGGINS, P. G. et al. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents, v. 35, n. 3, p. 305, 2010.
54. JAWAD, A. et al. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol, v. 36, n. 7, p. 1938-41, 1998.
55. JEON, B. C. et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J Clin Microbiol, v. 43, n. 5, p. 2241-5, 2005.
56. JIANG, W. et al. Study on the resistant genes to carbapenems and epidemiological characterization of multidrug-resistant Acinetobacter baumannii isolates. Microb Drug Resist, v. 19, n. 2, p. 117-23, 2013.
57. JOLLEY, K. A.; MAIDEN, M. C. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics, v. 10, n. 11, p. 595, 2010.
58. JONES, R. N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis, v. 1, n. 42, Suppl. 1, p. S13-24, 2006.
59. KARAH, N. et al. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat, v. 15 n. 4, p. 237-47, 2012.
60. KIFFER, C. et al. MYSTIC Brazil Group. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis, v. 9, n. 3, p. 216-24, 2005a.
61. KIFFER, C. R. et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis, v. 52, n. 4, p. 317-22, 2005b.
62. KIM, C. K. et al. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182. Diagn Microbiol Infect Dis, v. 68, n. 4, p. 432-8, 2010.
63. KIRATISIN, P. et al. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents, v. 36, n. 3, p. 243-6, 2010.
64. KOH, T. H. et al. IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore. J Antimicrob Chemother, v. 59, n. 4, p. 627-32, 2007.
65. KULAH, C. et al. Characterization of carbapenem-resistant Acinetobacter baumannii outbreak strains producing OXA-58 in Turkey. Int J Antimicrob Agents, v. 36, n. 2, p. 114-8, 2010.
66. LEE, K. et al. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents, v. 33, n. 6, p. 520-4, 2009.
67. LEE, Y. et al. Dissemination of ceftazidime-resistant Acinetobacter baumannii clonal complex 92 in Korea. J Appl Microbiol, v.112, n. 6, p. 1207-11, 2012.
68. LEVIN, A. S. et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis, v. 28, n. 5, p. 1008-11, 1999.
69. LEVIN, A. S. et al. Severe nosocomial with imipenemresistant Acinetobacter baumannii treated with ampicillin/ sulbactam. Int J Antimicrob Agents, v. 21, n. 1, p. 58-62, 2003.
70. LIAKOPOULOS, A. et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill, v. 15, n. 17, p. 11, 2012.
71. LIANG, W. et al. Activities of colistin-and minocyclinebased combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis, v. 27, n. 11, p. 109, 2011.
72. LIM, T. P. et al. In vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenemresistant Acinetobacter baumannii in Singapore. PLoS One, v. 6, n. 4, e18485, p.1-7, 2011.
73. LIN, W. R. et al. Rapid control of a hospital-wide outbreak caused by extensively drug-resistant OXA-72-producing Acinetobacter baumannii. Kaohsiung J Med Sci, v. 27, n. 6, p. 207-14, 2011.
74. LU, P. L. et al. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother, v. 63, n. 4, p. 641-7, 2009.
75. MADIGAN, M. T.; MARTINKO, J. M.; PARKER, J. Microbiologia de Brock. 12. ed. Porto Alegre: ArtMed, 2010. p. 535-43.
76. MAGIORAKOS, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, v.18, n. 3, p. 268-81, 2012.
77. MAHGOUB, S. et al. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control, v. 30, n. 7, p. 386-90, 2002.
78. MANAGEIRO, V. et al. Genetic diversity and clonal evolution of carbapenem-resistant Acinetobacter baumannii isolates from Portugal and the dissemination of ST118. Int J Antimicrob Agents, v. 40, n. 5, p. 398-403, 2012.
79. MANSOUR, W. et al. Dissemination of OXA-23-producing and carbapenem-resistant Acinetobacter baumannii in a University Hospital in Tunisia. Microb Drug Resist, v. 14, n. 4, p. 289-92, 2008.
80. MARAGAKIS, L. L.; PERL, T. M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis, v. 46, n. 8, p.1254-63, Review, 2008.
81. MARQUÉ, S. et al. Regional occurrence of plasmidmediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol, v. 43, n. 9, p. 4885-8, 2005.
82. MARQUES, M. B. et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother, v. 41, n. 5, p. 881-5, 1997.
83. MARRA, A. R. et al. Bloodstream infections with metallo-beta-lactamase- producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother, v. 50, n. 1, p. 388-90, 2006.
84. MARRA, A. R. et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol, v. 49, n. 5, p. 1866-71, 2011.
85. MARTINS, A. F. et al. Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme: dissemination in Southern Brazil. Infection, v. 37, n. 5, p. 474-6, 2009.
86. MARTINS, A. F. et al. High endemic levels of multidrugresistant Acinetobacter baumannii among hospitals in southern Brazil. Am J Infect Control, v. 40, n. 2, p.108-12, 2012.
87. MARTINS, A. F.; BARTH, A. L. Acinetobacter multirresistente - um desafio para a saúde pública. Sci Med, v. 23, n. 1, p. 56-62, 2013.
88. MEDEIROS, M. et al. Carbapenem-resistant Acinetobacter baumannii strains carrying blaOXA-72, blaOXA-58, blaOXA-23 andblaOXA-143 oxacillinase genes in southeastern Brazil. 2° Simpósio Internacional de Microbiologia Clínica (SIMC), Florianópolis, Santa Catarina, Brasil, 2010, n.102-2.
89. MEDEIROS, M. et al. Fatal outbreak of OXA-143-producing Acinetobacter baumannii, Belo Horizonte, Brazil. 26° Congresso Brasileiro de Microbiologia (CBM), Foz do Iguaçu, Paraná, Brasil, 2011, n.1751-1.
90. MEDEIROS, M. Avaliação in vitro e in vivo de efeitos sinérgicos de antibacterianos para o tratamento de infecções por Acinetobacter baumannii multirresistentes produtoras de carbapenemases tipo OXA endêmicas no Brasil. 2012. Dissertação (mestrado) - Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo. 2012.
91. MENDES, R. E. et al. Metallo-ß-lactamase. J Bras Patol Med Lab, v. 42, n. 2, p. 103-13, 2006.
92. MERKIER A. K. et al. Polyclonal spread of bla(OXA-23) and bla(OXA-58) in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries, v. 2, n. 3, p. 235-40, 2008.
93. MICHALOPOULOS, A.; FALAGAS, M. E. Colistin and polymyxin B in critical care. Crit Care Clin, v. 24, n. 2, p. 377-91, 2008.
94. MOHR, J. F. et al. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis, v. 44, n. 12, p.1536-42, 2007.
95. MOLAND, E. S. et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother, v. 52, n. 8, p. 2940-2, 2008.
96. MOREIRA, L. B. Princípios para o uso racional de antimicrobianos. Revista da AMRIGS, n. 2, p.73-152, 2004.
97. MOSTACHIO, A. K. et al. Multiplex PCR for rapid detection of genes encoding oxacillinases and metallo-beta-lactamases in carbapenem-resistant Acinetobacter spp. J Med Microbiol, v. 58, n. 11, p. 1522-4, 2009.
98. MOSTACHIO, A. K. et al. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int J Antimicrob Agents, v. 39, n. 5, p. 396-401, 2012.
99. MOURA, J. P.; GIR, E. Conhecimento dos profissionais de enfermagem referente à resistência bacteriana a múltiplas drogas. Acta Paul Enferm, v. 20, n. 3, p. 351-6, 2007.
100. MUGNIER, P. et al. Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates. Clin Microbiol Infect, v. 14, n. 9, p. 879-82, 2008.
101. MUGNIER, P. D. et al. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis, v. 16, n. 1, p. 35-40, 2010.
102. MUNOZ-PRICE, L. S.; WEINSTEIN, R. A. Acinetobacter infection. N Engl J Med, v. 358, n. 12, p. 1271-81, 2008.
103. NELSON, M. L. Chemical and biological dynamics of tetracyclines. Adv Dent Res, v. 12, n. 2, p. 5-11, Review, 1998.
104. NIGRO, S.J.; HALL, R. M. Tn6167, an antibiotic resistance island in an Australian carbapenem-resistant Acinetobacter baumannii GC2, ST92 isolate. J Antimicrob Chemother, v. 67, n. 6, p.1342-6, 2012.
105. NIUMSUP, P. R.et al. Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand. Jpn J Infect Dis, v. 62, n. 2, p. 152-4, 2009.
106. NOSKIN, G. A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis, v. 41, Suppl 5, p. S303-14, Review, 2005.
107. NOWAK, P. et al. Distribution of blaOXA genes among carbapenem-resistant Acinetobacter baumannii nosocomial strains in Poland. New Microbiol, v. 35, n. 3, p. 317-25, 2012.
108. OLIVEIRA, M. S.et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother, v. 61, n. 6, p.1369-75, 2008.
109. OLIVEIRA, M. L. et al. Dissemination of oxa carbapenemases genes in carbapenem resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th International Congress of Pharmaceutical Sciences, Ribeirão Preto, São Paulo, Brasil, 2011, n. PI 024.
110. OLIVEIRA, S. et al. Dissemination of KPC-2-producing Klebsiella pneumoniae and OXA-23-positive Acinetobacter baumannii in urban rivers, São Paulo, Brazil. In: 26° Congresso Brasileiro de Microbiologia (CBM), Foz Iguaçu, Paraná, Brasil, 2011, n. 2017-2.
111. PACHÓN-IBÁÑEZ, M. E. et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother, v. 48, n. 11, p. 4479-81, 2004.
112. PANKEY, G. A. Tigecycline. J Antimicrob Chemother, v. 56, n. 3, p. 470-80, 2005.
113. PANKEY, G. A.; ASHCRAFT, D. S. The detection of synergy between meropenem and polymyxin B against meropenemresistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis, v. 63, n. 2, p. 228-32, 2009.
114. PAPA, A. et al. Molecular epidemiology of carbapenemresistant Acinetobacter baumannii in a newly established Greek hospital. Microb Drug Resist, v. 15, n. 4, p. 257-60, 2009.
115. PECK, K. R. et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin-or tigecycline-resistant isolates. J Med Microbiol, v. 61, n. 3, p. 353-60, 2012.
116. PEI, G. et al. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenemresistant Acinetobacter baumannii. Microb Drug Resist, v. 18, n. 6, p. 574-7, 2012.
117. PELEG, A. Y. et al. OXA-58 and IMP-4 carbapenemhydrolyzing beta-lactamases in an Acinetobacter junii blood culture isolate from Australia. Antimicrob Agents Chemother, v. 50, n. 1, p. 399-400, 2006.
118. PELEG, A. Y. et al. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev, v. 21, n. 3, p. 538-82, 2008.
119. PEREZ, F. et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, v. 51, n. 10, p. 3471-84, 2007.
120. PETERSEN, P. J. et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother, v. 57, n. 3, p.573-6, 2006.
121. PETROSILLO, N. et al. Some current issues in the pharmacokinetics/ pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol, v. 76, n. 7, p. 509-24, Review, 2010.
122. POGUE, J. M. et al. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther, v. 11, n. 4, p. 383-93, 2013.
123. POIREL, L. et al. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother, v. 49, n. 1, p. 202-8, 2005.
124. POIREL, L. et al. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother, v. 54, n. 1, p. 24-38, Review, 2010.
125. POURNARAS, S. et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother, v. 57, n. 3, p. 557-61, 2006.
126. PRINCIPE, L. et al. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob, v. 21, n. 8, p.18, 2009.
127. QUEENAN, A. M.; BUSH, K. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev, v. 20, n. 3, p. 440-58, Review, 2007.
128. RAMÍREZ, M. S. et al. Spreading of AbaR-type genomic islands in multidrug resistance Acinetobacter baumannii strains belonging to different clonal complexes. Curr Microbiol, DOI 10.1007/s00284-013-0326-5, 2013.
129. RATTAN, A. et al. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis, v. 4, n. 2, p.195-209, Review, 1998.
130. REIS, A. O. et al. Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg Infect Dis, v. 9, n. 8, p. 1025-7, 2003.
131. REYNOLDS, P. E. Structure, biochemistry and mechanism of action of glycopeptides antibiotics. Eur J Clin Microbiol Infect Dis, v. 8, n. 11, p. 943-50, Review, 1989.
132. RIBEIRO, J. et al. Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program. J Chemother, v. 18, n. 5, p. 461-7, 2006.
133. RODRIGUEZ, C. H. et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries, v. 4, n. 3, p. 164-7, 2010.
134. RUNNEGAR, N. et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period. J Clin Microbiol, v. 48, n. 11, p. 4051-6, 2010.
135. SADER, H. S. et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, v. 5, n. 4, p. 200-14, 2001.
136. SADER H. S. et al. Dissemination and diversity of metallo-®- lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program International Int J Antimicrob Agents, v. 25, p. 57-61, 2005.
137. SAUVAGE, E. et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev, v. 32, n. 2, p. 234-58, 2008.
138. SAVOV, E. et al. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents, v. 20, n. 5, p. 390-2, 2002.
139. SCAIFE, W. et al. Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother, v. 36, n. 3, p. 585-6, 1995.
140. SCHIMITH BIER, K. E. et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control, v. 38, n. 4, p. 308-14, 2010.
141. SHENG, W. H. et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis, v. 70, n. 3, p. 380-6, 2011.
142. SOPIRALA, M. M. et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pandrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, v. 54, n. 11, p. 4678-83, 2010.
143. STIETZ, M. S. et al. Acinetobacter baumannii extensively drug resistant lineages in Buenos Aires hospitals differ from the international clones I-III. Infect Genet Evol, v. 14, p. 294-301, 2013.
144. STOEVA, T. et al. Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. Clin Microbiol Infect, v. 14, n. 7, p. 723-7, 2008.
145. TAN, T.Y. et al. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother, v. 60, n. 2, p. 421-3, 2007.
146. TAN, T. Y. et al. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother, v. 55, n. 1, p. 436-8, 2011.
147. TATMAN-OTKUN, M. et al. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol, v. 27, n. 1, p. 21-8, 2004.
148. TIAN, G. B. et al. Identification of diverse OXA-40 group carbapenemases, including a novel variant, OXA-160, from Acinetobacter baumannii in Pennsylvania. Antimicrob Agents Chemother, v. 55, n. 1, p. 429-32, 2011.
149. TILLOTSON, G. S. Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective? Expert Rev Anti Infect Ther, v. 6, n. 5 p. 551-2, 2008.
150. TOGNIM, M. C. et al. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis, v. 8, n. 5, p. 284-91, 2004.
151. UNAL, S.; GARCIA-RODRIGUEZ, J. A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis, v. 53, n. 4, p. 265-71, 2005.
152. YANG, H. Y. et al. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. Yonsei Med J, v. 50, n. 6, p. 764-70, 2009.
153. YOON, J. et al. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, v. 48, n. 3, p. 753-7, 2004.
154. WANG, H. et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother, v. 51, n. 11, p. 4022-8, 2007.
155. WAREHAM, D. W.; BEAN, D. C. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob, v. 21, n. 5, p. 10, 2006.
156. WERNECK, J. S. et al. OXA-72-producing Acinetobacter baumannii in Brazil: a case report. J Antimicrob Chemother, v. 66, n. 2, p. 452-4, 2011.
157. WERNECK, J. S. et al. Low prevalence of blaOXA-143 in private hospitals in Brazil. Antimicrob Agents Chemother, v. 55, n. 9, p. 4494-5, 2011.
158. WISPLINGHOFF, H. et al. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis, v. 31, n. 3, p. 690-7, 2000.
159. WOODFORD, N. et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents, v. 27, n. 4, p. 351-3, 2006.
160. ZAVASCKI, A. P. et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother, v. 60, n. 6, p.1206-15, 2007.
161. ZHANG, J. P. et al. Molecular characteristics and resistant mechanisms of imipenem-resistant Acinetobacter baumannii isolates in Shenyang, China. J Microbiol, v. 48, n. 5, p. 689-94, 2010.
162. ZHOU, H. et al. Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. J Med Microbiol, v. 56, n. 8, p.1076-80, 2007.